Addressing Bioanalytical Needs of Antibody-Based Biotherapeutics by LC-MS

LC-MS has become a major platform for the bioanalysis of protein biotherapeutics. The ease of method development and the high selectivity has been the key driving factor for the popularity of hybrid LC-MS/MS for bioanalysis of antibody-based biotherapeutics in preclinical species. LBA is still the dominant platform for biotherapeutic bioanalysis for clinical studies. The application of LC-MS to address bioanalytical questions of antibody- based biotherapeutics will rise as we improve the immunocapture and digestion methodology.

Click to rate this post!
[Total: 1 Average: 5]